Drug intelligence / Profile preview

VLPDEN-02 + ALFQ adjuvant

Development stage: Unknown
Lead developer: VLP Therapeutics
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

VLPDEN-02 + ALFQ adjuvant is an investigational tetravalent dengue virus-like particle (VLP) vaccine being developed by VLP Therapeutics. The vaccine consists of non-replicating virus-like particles engineered using structure-based design to display the structural proteins (prM and E) of all four dengue virus serotypes (DENV-1, DENV-2, DENV-3, and DENV-4) without containing any viral genome. It is formulated with the Army Liposome Formulation with QS-21 (ALFQ) adjuvant to enhance immunogenicity. VLPDEN-02 + ALFQ adjuvant is designed to elicit broadly neutralizing antibody responses against all four dengue serotypes and is being evaluated in Phase 1 clinical trials for the prevention of dengue fever.

Other names: tetravalent dengue VLP vaccinetetravalent dengue virus-like particle vaccineVLPDEN-02VLPDEN02VLPDEN 02VLPDEN-02 + ALFQ

Targets

DENV-1 E (Dengue virus serotype 1 envelope protein)Dengue virus type 2 envelope proteinDengue virus type 3 envelope proteinDengue virus type 4 envelope proteinDENV-2 E (Dengue virus serotype 2 envelope protein)DENV-3 E (Dengue virus serotype 3 envelope protein)DENV-4 E (Dengue virus serotype 4 envelope protein)

Beyond the preview

Go deeper on VLPDEN-02 + ALFQ adjuvant.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VLPDEN-02 + ALFQ adjuvant.